安进生物技术咨询（上海）有限公司申请I类会议

Group 1 - The core point of the news is that Amgen Biotechnology Consulting (Shanghai) Co., Ltd. has applied for an "I-class meeting" to address significant safety and technical issues in drug clinical trials and breakthrough therapies, with the current status being "in process" [1] - The I-class meeting is typically held within 30 days of the application and is aimed at resolving major safety issues encountered during clinical trials or significant technical problems in the development of breakthrough therapies [1] - Amgen Biotechnology Consulting (Shanghai) Co., Ltd. was established in 2012, is located in Shanghai, and primarily engages in research and experimental development, with a registered capital of 1 million RMB and paid-in capital of 1 million RMB [1] Group 2 - The major shareholder of Amgen Biotechnology Consulting (Shanghai) Co., Ltd. is Amgen Asia Holdings Limited, which holds 100% of the shares [2]